Cara Therapeutics | CARA - Net Income


Cara Therapeutics reported $-6.8M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Cassava Sciences USD -10.33M 2.21M Mar/2026
Chugai Pharma JPY 116.33B 913M Jun/2026
Cipla INR 7.89B 2.34B Jun/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.67M 64.51M Mar/2026
CSL USD 401M 96.5M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
J&J USD 5.53B 299M Jun/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Pacira USD 4.65M 1.74M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
RedHill Biopharma USD -1.54M 0 Jun/2024
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024